Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Recommendation of “Moderate Buy” from Analysts

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $15.50.

ACHV has been the topic of several research analyst reports. Citigroup assumed coverage on shares of Achieve Life Sciences in a research report on Tuesday, November 25th. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Citizens Jmp initiated coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price target on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Achieve Life Sciences in a report on Monday, November 24th.

Institutional Investors Weigh In On Achieve Life Sciences

A number of institutional investors have recently bought and sold shares of ACHV. AQR Capital Management LLC bought a new stake in Achieve Life Sciences in the 1st quarter valued at $32,000. Next Capital Management LLC acquired a new stake in shares of Achieve Life Sciences during the 3rd quarter valued at about $51,000. Jefferies Financial Group Inc. bought a new stake in Achieve Life Sciences in the fourth quarter valued at about $84,000. HRT Financial LP acquired a new position in Achieve Life Sciences in the fourth quarter worth about $93,000. Finally, OneDigital Investment Advisors LLC bought a new position in Achieve Life Sciences during the third quarter worth about $63,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Stock Down 3.5%

ACHV opened at $4.13 on Friday. The business has a 50 day moving average of $4.78 and a 200-day moving average of $3.99. The stock has a market capitalization of $219.84 million, a price-to-earnings ratio of -2.99 and a beta of 1.82. The company has a current ratio of 5.14, a quick ratio of 5.14 and a debt-to-equity ratio of 0.26. Achieve Life Sciences has a 1-year low of $1.84 and a 1-year high of $6.03.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.